RxDoctor Payments Data

Heather Wolfe

Family · Spring, TXNPI 1285265595

Payments from drug & device makers

$959in general payments, 2019–2025

Across 75 payments — averaging $12.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$292
  • Esperion Therapeutics, Inc.$162
  • Amgen$152
  • Biotronik Inc.$114
  • AstraZeneca$42
  • E.r. Squibb & Sons, L.L.C.$39
  • plus $157 from 7 others

What the payments were for

  • Food & beverage$959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$959 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$41,531
Medicare patients
387
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban333$310,840
Repatha SureclickEvolocumab227$128,044
JardianceEmpagliflozin92$95,975
EntrestoSacubitril/Valsartan78$88,955
XareltoRivaroxaban28$33,452
FarxigaDapagliflozin Propanediol14$11,373
BrilintaTicagrelor24$10,750
VascepaIcosapent Ethyl14$6,597
Metoprolol Succinate471$5,535
Atorvastatin Calcium301$3,889
Ranolazine ErRanolazine28$3,735
Ezetimibe171$3,609
Amlodipine Besylate286$2,113
Isosorbide Mononitrate ErIsosorbide Mononitrate188$1,957
Torsemide96$1,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$292$88,95578 claims
Johnson & JohnsonXarelto$19$33,45228 claims
AstraZenecaFarxiga, Brilinta$42$22,12338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 15,456 family providers in Texas.

Other family in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →